GlassScriptPhysician profile
Cassandra Digby
NPI 1164817607
$5,007.74
in general payments reported to CMS, 2019-2025
28 companies · $964 in 2025
The $964 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $988 · 2022: $1,033 · 2023: $1,056 · 2024: $967 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585 · Education: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.31 |
| Education | $401.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,074.17 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $629.58 | 2022-2025 | Sotyktu |
| Abbvie INC. | $531.59 | 2021-2025 | |
| Janssen Biotech, INC. | $514.89 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Regeneron Healthcare Solutions, INC. | $349.23 | 2021-2025 | Dupixent |
| Genzyme Corporation | $288.23 | 2021-2024 | |
| Lilly USA, LLC | $281.40 | 2021-2025 | Ebglyss, Taltz |
| Amgen INC. | $230.28 | 2022-2025 | Otezla, Otezla |
| Pfizer INC. | $204.34 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $147.63 | 2021-2025 | |
| Galderma Laboratories, L.P. | $138.64 | 2022-2025 | Nemluvio |
| Ucb, INC. | $128.67 | 2022-2025 | Bimzelx, Cimzia |
| Boston Scientific Corporation | $126.01 | 2024-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Arcutis Biotherapeutics, INC. | $59.20 | 2023-2025 | Zoryve |
| Organogenesis INC. | $45.94 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $32.41 | 2023 | Adbry |
| Mimedx Group, INC. | $29.59 | 2024 | |
| Mallinckrodt Hospital Products INC. | $24.42 | 2025 | Acthar |
| Genentech USA, INC. | $23.53 | 2023 | Erivedge |
| Janssen Scientific Affairs, LLC | $20.14 | 2021 | |
| Botanix Sb INC | $19.72 | 2025 | Sofdra |
| Biofrontera INC. | $19.44 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.40 | 2025 | Cabtreo |
| Mayne Pharma Commercial LLC | $15.04 | 2023-2024 | |
| Smith+Nephew, INC. | $14.97 | 2023 | Collagenase Santyl |
| Verrica Pharmaceuticals INC. | $14.90 | 2023 | Ycanth |
| Organon LLC | $14.40 | 2025 | Vtama |
| Dermavant Sciences, INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Digby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.